Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Two-Drug combo supercharge weight loss?

NCT ID NCT06373146

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding a second drug (mibavademab) to the weight-loss medication tirzepatide helps adults with obesity lose more weight than tirzepatide alone. About 392 participants with a BMI between 30 and 40 took part. The goal was to measure changes in body weight over 74 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

392 people

The number who actually took part.

Started

Apr 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a body mass index (BMI) of ≥30 kilogram/square meter (kg/m²) and ≤40 kg/m² * Willing to learn how to self-inject study intervention (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study intervention; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study intervention) * Male or female contraceptive use by participant should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: * Have a history of diabetes mellitus, including Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM), history of ketoacidosis, or hyperosmolar state/coma * Have a self-reported change (increase or decrease) in body weight \>5 kilogram (kg) within 3 months prior to screening * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2 * Have acute or chronic hepatitis * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • CTI Clinical Research Center

    Cincinnati, Ohio, 45212, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Hassman Research Institute Marlton Site

    Marlton, New Jersey, 08053, United States

  • Irvine Clinical Research

    Irvine, California, 92614, United States

  • Juno Research

    Houston, Texas, 77040, United States

  • Lillestol Research

    Fargo, North Dakota, 58104, United States

  • Northwest Clinical Research Center

    Bellevue, Washington, 98007, United States

  • Solaris Clinical Research

    Meridian, Idaho, 83646, United States

  • South Texas Clinical Research

    Corpus Christi, Texas, 78404, United States

  • Tandem Clinical Research

    Marrero, Louisiana, 70072, United States

  • Velocity Clinical Research - New Orleans

    New Orleans, Louisiana, 70119, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Velocity Clinical Research, Gardena

    Gardena, California, 90247, United States

  • Velocity Clinical Research, Los Angeles

    Los Angeles, California, 90017, United States

  • Velocity Clinical Research, North Hollywood

    North Hollywood, California, 91606, United States

  • Velocity Clinical Research, Panorama City

    Van Nuys, California, 91405, United States

  • Velocity Clinical Research, Santa Ana

    Santa Ana, California, 92704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.